Introduction {#bjs10889-sec-0005}
============

The pivotal trials showing equivalent oncological outcomes after breast‐conserving surgery (BCS) with adjuvant whole‐breast radiotherapy (RT) and after mastectomy were conducted decades ago[1](#bjs10889-bib-0001){ref-type="ref"}, [2](#bjs10889-bib-0002){ref-type="ref"}. Data from these trials have been crucial to change in the understanding of local treatment of breast cancer, but since then the scenario has changed substantially. Survival rates are increasing, probably owing to a combination of decreasing tumour size and fewer patients presenting with node‐positive disease at diagnosis. At the same time, the use of adjuvant treatment has increased markedly, and is currently based more on tumour biology than disease stage.

In recent years, several large retrospective analyses of contemporary data[3](#bjs10889-bib-0003){ref-type="ref"}, [4](#bjs10889-bib-0004){ref-type="ref"}, [5](#bjs10889-bib-0005){ref-type="ref"} have suggested the stage‐adjusted superiority of BCS over mastectomy in early breast cancer in terms of breast cancer‐specific survival and overall survival. Other publications have focused on young women[6](#bjs10889-bib-0006){ref-type="ref"}, [7](#bjs10889-bib-0007){ref-type="ref"}, [8](#bjs10889-bib-0008){ref-type="ref"} or triple‐negative breast cancer[9](#bjs10889-bib-0009){ref-type="ref"}, with the results indicating that BCS is at least as good as mastectomy in terms of survival outcomes. This interesting finding has led some authors to question whether mastectomy without RT should be offered at all as a treatment alternative for early breast cancer[10](#bjs10889-bib-0010){ref-type="ref"}, or whether it is time to abandon the 'mastectomy myth'[11](#bjs10889-bib-0011){ref-type="ref"}. A convincing explanation for these observations is still lacking, and there might be explanatory factors that were not adjusted for in the mostly retrospective, non‐randomized published studies.

Locoregional recurrence rates have reportedly been higher after BCS than mastectomy[2](#bjs10889-bib-0002){ref-type="ref"}, [12](#bjs10889-bib-0012){ref-type="ref"}, and especially so in triple‐negative and human epidermal growth factor receptor 2 (HER2)‐positive breast cancer[13](#bjs10889-bib-0013){ref-type="ref"}, although contradictory results were reported by Zumsteg and colleagues[9](#bjs10889-bib-0009){ref-type="ref"}. Unfortunately, locoregional recurrence rates were rarely available in the abovementioned retrospective studies, as few registries provided reliable data on these events. Therefore, it has not been clearly shown whether locoregional recurrence is truly a more common event after BCS than mastectomy. Likewise, it could not be elucidated whether locoregional recurrences may explain the observed differences in survival after BCS and mastectomy.

Despite their impressive population sizes, retrospective observational analyses are not only prone to selection effects, but frequently also lack data on recurrence and oncological treatments administered. Therefore, the present analysis was performed using data from the Swedish Multicentre Cohort Study, in which patients were enrolled prospectively and followed up regularly, with the aim of comparing survival and locoregional recurrence rates following BCS with RT and mastectomy without RT.

Methods {#bjs10889-sec-0006}
=======

Between September 2000 and January 2004, the prospective Swedish Multicentre Cohort Study enrolled patients with breast cancer from 26 Swedish hospitals. Level I and II completion axillary lymph node dissection (ALND) was undertaken only in patients with sentinel node‐positive disease. Completion ALND was carried out if no sentinel lymph node could be identified. Inclusion criteria were: primary unifocal, clinically node‐negative invasive breast cancer smaller than 30 mm in diameter at preoperative staging. Preoperative imaging comprised mammography and/or ultrasonography; MRI was not part of the study protocol. Patients whose tumours exceeded 30 mm in size on final histopathological examination no longer fulfilled the inclusion criteria and were excluded. Exclusion criteria were: neoadjuvant chemotherapy and/or RT, pregnancy, previous allergic reaction to blue dye or isotope, previous ipsilateral breast surgery and suspected tumour multifocality. The injection techniques used for sentinel node biopsy have been described in detail elsewhere[14](#bjs10889-bib-0014){ref-type="ref"}, [15](#bjs10889-bib-0015){ref-type="ref"}. Written informed consent was obtained from all patients before enrolment. The study was approved by the central ethics committee in Stockholm and the individual regional ethics committees before study initiation (no. 00‐053; updated in 2015, no. 2015/979‐32).

Follow‐up was scheduled as annual mammography and clinical examination; however, telephone interviews by trained nurses were performed instead by a few centres. The recently updated database includes follow‐up reports from each participating hospital submitted in autumn 2016 (last visit, incidence of breast cancer relapse, tumour location, contralateral breast cancer and death).

For the present analysis, patients were selected from the above cohort who met following additional criteria: they had to have follow‐up within Sweden and have a confirmed invasive breast cancer on histopathology. Surgical axillary staging had to have been performed. Patients with previous or synchronous breast cancer were excluded. To restrict the selection of patients to those with early breast cancer, patients with a pathological tumour size larger than 30 mm or more than nine positive lymph nodes on ALND were also excluded, as were a few patients with distant metastases diagnosed within 2 months of study inclusion. To compare patients treated by BCS followed by whole‐breast RT with patients undergoing mastectomy without RT, all other local treatment strategies were excluded (*Fig*. [1](#bjs10889-fig-0001){ref-type="fig"}).

![Flow chart showing the selection of patients for the present analysis. BCS, breast‐conserving surgery; RT, radiotherapy](BJS-105-1607-g002){#bjs10889-fig-0001}

Breast cancer death was defined as death from breast cancer, and patients were censored either at the date of death or last date of follow‐up if no breast cancer death had occurred. Data on breast cancer as a cause of death were received both from participating centres and from the national cause of death database. Isolated axillary recurrence was defined as an axillary nodal recurrence, without a concurrent ipsilateral in‐breast recurrence diagnosed within 3 months before or after the axillary recurrence. Patients without any breast cancer event were censored at the date of last follow‐up.

Statistical analysis {#bjs10889-sec-0007}
--------------------

The initial power calculation has been described elsewhere[15](#bjs10889-bib-0015){ref-type="ref"}; in the main trial, the primary endpoint was axillary recurrence. In the present study, breast cancer‐specific survival was calculated from the date of operation to the date of breast cancer death or the date of last clinical follow‐up, if death did not occur. Overall survival was calculated from the date of surgery to the date of death from any cause, or the date of last follow‐up noted in the electronic patient charts, which are automatically linked to the population register containing information on death and date of death.

Descriptive data are presented as numbers with percentages and median (range). The Mann--Whitney U test was used for comparison of continuous variables in the two local treatment groups. The χ^2^ test or Fisher\'s exact test, as appropriate, was used for analysis of the distribution of categorical variables between the groups.

Survival analysis was first performed by the Kaplan--Meier method, with comparison of survival curves by means of the log rank test. Cox proportional hazards regression analysis was then added to adjust the results for tumour and patient characteristics. All variables listed in Table  [1](#bjs10889-tbl-0001){ref-type="table"} were included in the multivariable regression analysis, regardless of their significance on univariable regression. Surrogate tumour subtypes were not included to avoid confounding with the underlying factors already included in the analysis. Results are presented as hazard ratios (HRs) with 95 per cent confidence intervals.

###### 

Patient and tumour characteristics according to local treatment combination

                                                                       BCS with RT (n = 2338)   Mastectomy without RT (n = 429)      P [†](#bjs10889-note-0003){ref-type="fn"}
  ------------------------------------------------------------------- ------------------------ --------------------------------- -------------------------------------------------
  Patient age (years)[\*](#bjs10889-note-0002){ref-type="fn"}               58 (23--88)                   63 (28--94)             \< 0·001[‡](#bjs10889-note-0004){ref-type="fn"}
  \< 41                                                                       86 (3·7)                     22 (5·1)                                  \< 0·001
  41--50                                                                     413 (17·7)                    58 (13·5)             
  51--65                                                                    1276 (54·6)                   165 (38·5)             
  \> 65                                                                      563 (24·1)                   184 (42·9)             
  Invasive tumour size (mm)[\*](#bjs10889-note-0002){ref-type="fn"}          14 (1--30)                   16 (2--30)              \< 0·001[‡](#bjs10889-note-0004){ref-type="fn"}
  1--5                                                                        82 (3·5)                     15 (3·5)                                  \< 0·001
  6--10                                                                      497 (21·3)                    58 (13·5)             
  11--20                                                                    1413 (60·4)                   245 (57·1)             
  21--30                                                                     346 (14·8)                   111 (25·9)             
  Histological subtype                                                                                                                               \< 0·001
  Ductal                                                                    1627 (69·6)                   256 (59·7)             
  Lobular                                                                    233 (10·0)                    76 (17·7)             
  Other                                                                      145 (6·2)                     31 (7·2)              
  Ductal and lobular                                                          17 (0·7)                      5 (1·2)              
  Missing                                                                    316 (13·5)                    61 (14·2)             
  Multifocal tumour                                                                                                               \< 0·001[§](#bjs10889-note-0100){ref-type="fn"}
  Yes                                                                         88 (3·8)                     64 (14·9)             
  No                                                                        2250 (96·2)                   365 (85·1)             
  Nottingham Histological Grade                                                                                                                        0·030
  1                                                                          661 (28·3)                    95 (22·1)             
  2                                                                         1136 (48·6)                   225 (52·4)             
  3                                                                          469 (20·1)                    96 (22·4)             
  Missing                                                                     72 (3·1)                     13 (3·0)              
  Oestrogen receptor status                                                                                                        0·433[§](#bjs10889-note-0100){ref-type="fn"}
  Positive                                                                  1983 (84·8)                   369 (86·0)             
  Negative                                                                   309 (13·2)                    50 (11·7)             
  Missing                                                                     46 (2·0)                     10 (2·3)              
  Progesterone receptor status                                                                                                     0·905[§](#bjs10889-note-0100){ref-type="fn"}
  Positive                                                                  1639 (70·1)                   298 (69·5)             
  Negative                                                                   630 (26·9)                   116 (27·0)             
  Missing                                                                     69 (3·0)                     15 (3·5)              
  Pathological node category                                                                                                                           0·024
  pN0                                                                       1779 (76·1)                   348 (81·1)             
  pN1                                                                        489 (20·9)                    76 (17·7)             
  pN2                                                                         70 (3·0)                      5 (1·2)              
  Adjuvant treatment                                                                                                             
  Endocrine therapy                                                                                                                0·207[§](#bjs10889-note-0100){ref-type="fn"}
  Yes                                                                       1576 (67·4)                   303 (70·6)             
  No                                                                         722 (30·9)                   119 (27·7)             
  Missing                                                                     40 (1·7)                      7 (1·6)              
  Chemotherapy                                                                                                                    \< 0·001[§](#bjs10889-note-0100){ref-type="fn"}
  Yes                                                                        489 (20·9)                    52 (12·1)             
  No                                                                        1779 (76·1)                   372 (86·7)             
  Missing                                                                     70 (3·0)                      5 (1·2)              

Values in parentheses are percentages unless indicated otherwise;

values are median (range). BCS, breast‐conserving surgery; RT, radiotherapy.

χ^2^ test, except

Mann--Whitney U test and

Fisher\'s exact test.

All data analysis was performed using SPSS® version 22 (IBM, Armonk, New York, USA). Statistical significance was set at a level of 5 per cent for all analyses.

Results {#bjs10889-sec-0008}
=======

Overall and breast cancer‐specific survival according to local treatment {#bjs10889-sec-0009}
------------------------------------------------------------------------

Of 3518 patients enrolled in the Swedish Multicentre Cohort Study, 2767 remained in the analysis after applying the selection criteria (Fig. [1](#bjs10889-fig-0001){ref-type="fig"}); 429 patients underwent mastectomy without RT and 2338 had BCS followed by whole‐breast RT.

Median follow‐up was 156 (range 0--189) months; there was one postoperative death from cardiac failure. Overall, there were 653 deaths, translating into a 13‐year overall survival rate of 77·2 per cent for the entire cohort (79·5 per cent for BCS with RT and 64·3 per cent for mastectomy without RT; P \< 0·001) (Fig. [2](#bjs10889-fig-0002){ref-type="fig"}). A total of 277 patients died from breast cancer, with a 13‐year breast cancer‐specific survival rate of 89·6 per cent for the entire cohort (90·5 per cent for BCS with RT and 84·0 per cent for mastectomy without RT; P \< 0·001) (Fig. [3](#bjs10889-fig-0003){ref-type="fig"}).

![Kaplan--Meier survival curves showing overall survival in the two local treatment groups. BCS, breast‐conserving surgery; RT, radiotherapy. P \< 0·001 (log rank test)](BJS-105-1607-g003){#bjs10889-fig-0002}

![Kaplan--Meier survival curves showing breast cancer‐specific survival in the two local treatment groups. BCS, breast‐conserving surgery; RT, radiotherapy. P \< 0·001 (log rank test)](BJS-105-1607-g001){#bjs10889-fig-0003}

Patient and tumour characteristics are presented in *Table*  [1](#bjs10889-tbl-0001){ref-type="table"}. Notably, patients in the mastectomy group differed from those in the BCS group in terms of a higher percentage of lobular and multifocal tumours of a higher histological grade and larger size in an older population. In the BCS group, more patients had positive lymph nodes and had received chemotherapy. To allow for these group differences, survival outcomes were adjusted for all factors listed in *Table*  [1](#bjs10889-tbl-0001){ref-type="table"} in multivariable Cox regression analyses. These analyses showed that treatment with mastectomy without RT was an independent negative factor for overall survival (HR 1·70, 95 per cent c.i. 1·38 to 2·10), together with oestrogen receptor (ER) negativity, higher tumour grade, higher nodal category, tumour size above 20 mm and older age (*Table*  [2](#bjs10889-tbl-0002){ref-type="table"}). Findings were similar for breast cancer‐specific survival (*Table*  [3](#bjs10889-tbl-0003){ref-type="table"}); being treated by mastectomy without adjuvant RT was an independent negative factor (HR 1·69, 1·22 to 2·33), as were ER negativity, older age, higher tumour grade and higher nodal category.

###### 

Univariable and multivariable Cox regression analyses for overall survival

                                   Univariable analysis   Multivariable analysis                      
  ------------------------------- ---------------------- ------------------------ ------------------- ----------
  Age (years)                                                                                         
  \< 41                             0·20 (0·11, 0·37)            \< 0·001          0·16 (0·80, 0·34)   \< 0·001
  41--50                            0·22 (0·17, 0·30)            \< 0·001          0·21 (0·15, 0·30)   \< 0·001
  51--65                            0·40 (0·34, 0·47)            \< 0·001          0·41 (0·34, 0·49)   \< 0·001
  \> 65                              1·00 (reference)                              1·00 (reference)   
  Invasive tumour size (mm)                                                                           
  1--5                               1·00 (reference)                              1·00 (reference)   
  6--10                             0·98 (0·58, 1·67)             0·951            1·19 (0·59, 2·40)    0·625
  11--20                            1·47 (0·89, 2·42)             0·133            1·63 (0·83, 3·18)    0·154
  21--30                            2·26 (1·35, 3·79)             0·002            2·09 (1·05, 4·15)    0·036
  Histological subtype                                                                                
  Ductal                             1·00 (reference)                              1·00 (reference)   
  Lobular                           1·02 (0·80, 1·31)             0·850            0·79 (0·61, 1·03)    0·088
  Other                             0·85 (0·61, 1·18)             0·332            0·82 (0·57, 1·20)    0·317
  Ductal and lobular                0·35 (0·09, 1·41)             0·141            0·38 (0·09, 1·53)    0·172
  Multifocal tumour                                                                                   
  Yes                               1·04 (0·75, 1·45)             0·812            0·94 (0·65, 1·37)    0·756
  No                                 1·00 (reference)                              1·00 (reference)   
  Pathological node category                                                                          
  pN0                                1·00 (reference)                              1·00 (reference)   
  pN1                               1·37 (1·15, 1·64)             0·001            1·58 (1·27, 1·96)   \< 0·001
  pN2                               2·00 (1·36, 2·92)            \< 0·001          2·75 (1·77, 4·28)   \< 0·001
  Nottingham Histological Grade                                                                       
  1                                  1·00 (reference)                              1·00 (reference)   
  2                                 1·77 (1·44, 2·18)            \< 0·001          1·80 (1·39, 2·31)   \< 0·001
  3                                 2·09 (1·65, 2·64)            \< 0·001          2·23 (1·64, 3·02)   \< 0·001
  Oestrogen receptor status                                                                           
  Positive                           1·00 (reference)                              1·00 (reference)   
  Negative                          1·35 (1·09, 1·66)             0·005            1·45 (1·02, 2·05)    0·037
  Progesterone receptor status                                                                        
  Positive                           1·00 (reference)                              1·00 (reference)   
  Negative                          1·29 (1·09, 1·52)             0·003            0·98 (0·77, 1·23)    0·838
  Adjuvant chemotherapy                                                                               
  Yes                               1·17 (0·96, 1·44)             0·122            1·22 (0·92, 1·62)    0·174
  No                                 1·00 (reference)                              1·00 (reference)   
  Adjuvant endocrine therapy                                                                          
  Yes                                1·00 (reference)                              1·00 (reference)   
  No                                0·90 (0·75, 1·05)             0·176            1·00 (0·78, 1·29)    0·999
  Local treatment                                                                                     
  BCS with RT                        1·00 (reference)                              1·00 (reference)   
  Mastectomy without RT             1·87 (1·56, 2·24)            \< 0·001          1·70 (1·38, 2·10)   \< 0·001

Values in parentheses are 95 per cent confidence intervals. BCS, breast‐conserving surgery; RT, radiotherapy.

###### 

Univariable and multivariable Cox regression analyses breast cancer‐specific survival

                                   Univariable analysis   Multivariable analysis                      
  ------------------------------- ---------------------- ------------------------ ------------------- ----------
  Age (years)                                                                                         
  \< 41                             0·66 (0·34, 1·27)             0·216            0·43 (0·19, 0·96)    0·041
  41--50                            0·68 (0·48, 0·98)             0·039            0·63 (0·41, 0·97)    0·035
  51--65                            0·68 (0·52, 0·89)             0·005            0·72 (0·53, 0·99)    0·044
  \> 65                              1·00 (reference)                              1·00 (reference)   
  Invasive tumour size (mm)                                                                           
  1--5                               1·00 (reference)                              1·00 (reference)   
  6--10                             0·80 (0·30, 2·11)             0·653            0·88 (0·26, 3·02)    0·840
  11--20                            2·00 (0·82, 4·87)             0·127            1·80 (0·57, 5·70)    0·319
  21--30                            3·90 (1·58, 9·63)             0·003            2·39 (0·74, 7·71)    0·146
  Histological subtype                                                                                
  Ductal                             1·00 (reference)                              1·00 (reference)   
  Lobular                           0·99 (0·68, 1·44)             0·974            0·91 (0·60, 1·37)    0·648
  Other                             0·80 (0·47, 1·35)             0·400            0·96 (0·54, 1·70)    0·885
  Ductal and lobular                0·41 (0·06, 2·93)             0·375            0·38 (0·05, 2·79)    0·345
  Multifocal tumour                                                                                   
  Yes                               0·93 (0·54, 1·59)             0·783            0·84 (0·47, 1·50)    0·566
  No                                 1·00 (reference)                              1·00 (reference)   
  Pathological node category                                                                          
  pN0                                1·00 (reference)                              1·00 (reference)   
  pN1                               2·20 (1·70, 2·83)            \< 0·001          2·77 (1·63, 4·72)   \< 0·001
  pN2                               3·74 (2·33, 6·02)            \< 0·001          2·64 (1·93, 3·60)   \< 0·001
  Nottingham Histological Grade                                                                       
  1                                  1·00 (reference)                              1·00 (reference)   
  2                                 2·82 (1·89, 4·21)            \< 0·001          2·33 (1·48, 3·67)   \< 0·001
  3                                 5·30 (3·51, 8·00)            \< 0·001          3·88 (2·26, 6·37)   \< 0·001
  Oestrogen receptor status                                                                           
  Positive                           1·00 (reference)                              1·00 (reference)   
  Negative                          2·12 (1·60, 2·80)            \< 0·001          1·76 (1·05, 2·97)    0·033
  Progesterone receptor status                                                                        
  Positive                           1·00 (reference)                              1·00 (reference)   
  Negative                          1·80 (1·41, 2·30)            \< 0·001          1·21 (0·85, 1·71)    0·288
  Adjuvant chemotherapy                                                                               
  Yes                               0·65 (0·50, 0·85)             0·001            1·13 (0·94, 2·02)    0·101
  No                                 1·00 (reference)                              1·00 (reference)   
  Adjuvant endocrine therapy                                                                          
  Yes                                1·00 (reference)                              1·00 (reference)   
  No                                0·93 (0·72, 1·21)             0·593            0·89 (0·58, 1·37)    0·603
  Local treatment                                                                                     
  BCS with RT                        1·00 (reference)                              1·00 (reference)   
  Mastectomy without RT             1·76 (1·33, 2·33)            \< 0·001          1·69 (1·22, 2·33)    0·001

Values in parentheses are 95 per cent confidence intervals. BCS, breast‐conserving surgery; RT, radiotherapy.

Locoregional recurrence rates according to local treatment and impact on survival {#bjs10889-sec-0010}
---------------------------------------------------------------------------------

As the isolated axillary recurrence rate was the primary endpoint of the prospective cohort study, this outcome was compared between the two treatment groups. Overall, 41 isolated axillary recurrences were found (1·5 per cent): 26 (1·1 per cent) after BCS with RT and 15 (3·5 per cent) after mastectomy without RT (*P* = 0·001). The resulting 13‐year isolated axillary recurrence‐free survival rates were 98·3 and 96·2 per cent respectively (*P* \< 0·001). Median time to isolated axillary recurrence was 39 (range 4--157) months overall: 39·5 (10--157) months for BCS with RT and 39 (4--117) months for mastectomy without RT (*P* = 0·357). Of 41 isolated axillary recurrences, 31 occurred in patients with node‐negative disease.

Overall, 139 recurrences within the ipsilateral breast or chest wall were recorded, with 13‐year local recurrence‐free survival rates of 90·5 and 95·1 per cent in the BCS with RT and mastectomy without RT groups respectively (*P* = 0·428).

Both local recurrence and isolated axillary recurrence were strong independent predictors of breast cancer death, with HRs of 3·04 (95 per cent c.i. 2·05 to 4·50) and 4·28 (2·55 to 7·17) respectively when these events were added separately into the multivariable regression analysis performed previously. The same was true for overall survival as an endpoint in the case of isolated axillary recurrence, with a HR of 2·64 (1·66 to 4·19); local recurrence showed a near‐significant association with worse overall survival (HR 1·40, 1·00 to 1·96).

Independent risk factors for developing an isolated axillary recurrence on multivariable Cox regression analysis were undergoing mastectomy without adjuvant RT (HR 2·98, 1·44 to 6·17) and high histological grade (HR 3·94, 1·28 to 12·16). Even adjusting for the number of excised axillary lymph nodes did not change the HR for mastectomy without RT compared with BCS with RT; 12 of 15 cases of isolated axillary recurrence after mastectomy without RT were classified as node‐negative and the patients underwent sentinel node biopsy only.

Discussion {#bjs10889-sec-0011}
==========

This large prospective cohort study of early breast cancer with long follow‐up has confirmed the superiority of BCS with postoperative RT over mastectomy without RT in terms of breast cancer‐specific survival and overall survival. Although a number of explanatory factors, such as selection bias owing to co‐morbidity and socioeconomic factors, remain unknown, an increased axillary recurrence rate after mastectomy without RT may be one of several factors contributing to this finding. It is possible that tangential RT fields originating from whole‐breast RT after BCS exert some protective effect on axillary recurrence by controlling minimal residual disease, although this could not fully explain the survival advantage in patients treated with BCS with RT over those who underwent mastectomy without RT.

False‐negative rates in sentinel node biopsy range between 0 and 40 per cent, with a median of 7 per cent[16](#bjs10889-bib-0016){ref-type="ref"}. Despite this, axillary recurrences after a negative sentinel node biopsy are rare, which may be attributed to improved systemic therapies, unintended RT to the lower axilla by tangential fields in whole‐breast irradiation, and immunological processes. In the present cohort, the 10‐year axillary recurrence rate among node‐negative individuals was only 1·6 per cent[17](#bjs10889-bib-0017){ref-type="ref"}. Interestingly, most reports and reviews on axillary recurrence rates after a negative sentinel node biopsy without completion axillary dissection did not elaborate on differences between BCS and mastectomy[18](#bjs10889-bib-0018){ref-type="ref"}, [19](#bjs10889-bib-0019){ref-type="ref"}. One exception is the report from Milan by Galimberti and colleagues[20](#bjs10889-bib-0020){ref-type="ref"} on a cohort of 5262 patients with a median follow‐up of 7 years. In this study, both external‐beam RT and BCS were shown to be significantly protective of axillary recurrence as a first event; however, both lost statistical significance on multivariable analysis. From the same institution, Gentilini and co‐workers[21](#bjs10889-bib-0021){ref-type="ref"} recently published data on an interesting comparison of axillary recurrence rates in patients operated by BCS and irradiated by external‐beam whole‐breast RT or by intraoperative partial breast irradiation. The 10‐year cumulative incidence of axillary recurrence was significantly lower for those receiving whole‐breast RT (1·3 *versus* 4·0 per cent), clearly demonstrating an effect of unintentional RT to the lower axilla resulting from tangential fields in whole‐breast irradiation[21](#bjs10889-bib-0021){ref-type="ref"}.

The proportion of axillary levels I--II receiving 95 per cent of the isodose by standard tangential fields varies between 23 and 87 per cent (average 55 per cent)[22](#bjs10889-bib-0022){ref-type="ref"}; likewise, it was shown that between 5 and 80 (mean 48·7) per cent of the 50‐Gy RT dose intended for the breast reached the lower axilla[23](#bjs10889-bib-0023){ref-type="ref"}. It is therefore agreed that whole‐breast RT does not achieve adequate axillary coverage if high tangents are not used, as in the present study. Despite this, there is mounting clinical evidence that even standard tangential fields provide a degree of regional control. A 2011 review[24](#bjs10889-bib-0024){ref-type="ref"} reported that external‐beam whole‐breast irradiation decreased the rate of axillary recurrence after a negative sentinel node biopsy. Likewise, the watershed randomized trials on sentinel node‐positive patients not undergoing completion axillary dissection demonstrated much lower axillary recurrence rates than expected, only enrolling patients treated by BCS with mandatory whole‐breast irradiation[25](#bjs10889-bib-0025){ref-type="ref"}, [26](#bjs10889-bib-0026){ref-type="ref"}. Although it could be argued that systemic treatment effects must play a major part in these results in node‐positive populations, this is likely to have less impact in the present analysis as only a minority of patients received adjuvant chemotherapy.

An important drawback of the present analysis is that socioeconomic differences and co‐morbidities were not registered prospectively at the time of study, precluding the analysis of these potentially significant confounders. Furthermore, detailed information on irradiation doses and target volumes was not recorded, but high tangents were not in use in whole‐breast or chest‐wall irradiation. A major composite impact of these factors is certainly to be expected because the increased axillary recurrence rate, although significant, cannot explain the observed differences in survival rates. In addition, there were several significant baseline differences between the two groups, which in large part can be explained by the underlying selection mechanisms for the surgical methods studied. Multifocality, for example, is a known contributor to the surgical choice of mastectomy, but may at the same time represent both a risk factor for a false‐negative sentinel node biopsy[27](#bjs10889-bib-0027){ref-type="ref"}, [28](#bjs10889-bib-0028){ref-type="ref"} and for worse prognosis[29](#bjs10889-bib-0029){ref-type="ref"}. This factor, however, was not identified as an independent predictor in the adjusted analyses, which is in line with publications reporting that the type of surgery might not influence the association between multifocality and worse tumour characteristics and outcome[30](#bjs10889-bib-0030){ref-type="ref"}, [31](#bjs10889-bib-0031){ref-type="ref"}. The observed group differences do pose a substantial problem, but as randomized prospective trials in this area are unlikely to be undertaken in the near future, this large prospective cohort comes as close to a controlled setting as possible.

This large prospective cohort study has provided further support for the survival benefits resulting from BCS followed by whole‐breast irradiation in patients with early breast cancer. The data indicate a contributory role of partial RT coverage of the lower axillary levels in the avoidance of axillary recurrences; however, the improvements in breast cancer‐specific survival and overall survival call for further explanatory factors, and socioeconomic variables and co‐morbidity should receive closer scrutiny. The present data do not support the historical claim that there is a higher risk of local recurrence after BCS followed by RT.
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